Completed PHASE2 INTERVENTIONAL NCT00001487

Treatment of Mid-Life-Related Mood Disorders

Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men

Sponsor: National Institute of Mental Health (NIMH)

Conditions Depressive Disorder Mood Disorder

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Jun 30, 1995 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00001487, this PHASE2 trial focuses on Depressive Disorder and Mood Disorder and remains completed. Sponsored by National Institute of Mental Health (NIMH), it has been updated 5 times since 1995, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States